ATE100322T1 - Verwendung von uridin zur behandlung nervoeser stoerungen. - Google Patents

Verwendung von uridin zur behandlung nervoeser stoerungen.

Info

Publication number: ATE100322T1
Authority: AT; Austria
Prior art keywords: uridin; treatment; nervous disorders; uridine; schizophrenia
Prior art date: 1988-06-21

Application number

AT89830264T

Other languages

English (en)

Inventor

Luca Giovanna De

Stazio Giovanni Di

Mario Materazzi

Vincenzo Politi

Original Assignee

Polifarma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-21

Filing date

1989-06-14

Publication date

1994-02-15

1989-06-14 Application filed by Polifarma Spa filed Critical Polifarma Spa

1994-02-15 Application granted granted Critical

1994-02-15 Publication of ATE100322T1 publication Critical patent/ATE100322T1/de

Links

DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
102100025841 Cholecystokinin Human genes 0.000 abstract 1
101800001982 Cholecystokinin Proteins 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
210000005013 brain tissue Anatomy 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
229940107137 cholecystokinin Drugs 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
230000003291 dopaminomimetic effect Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 abstract 1
229940045145 uridine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

AT89830264T 1988-06-21 1989-06-14 Verwendung von uridin zur behandlung nervoeser stoerungen. ATE100322T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT48118/88A IT1219667B (it)	1988-06-21	1988-06-21	Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
EP89830264A EP0348360B1 (de)	1988-06-21	1989-06-14	Verwendung von Uridin zur Behandlung nervöser Störungen

Publications (1)

Publication Number	Publication Date
ATE100322T1 true ATE100322T1 (de)	1994-02-15

Family

ID=11264638

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT89830264T ATE100322T1 (de)	1988-06-21	1989-06-14	Verwendung von uridin zur behandlung nervoeser stoerungen.

Country Status (8)

Country	Link
US (1)	US4960759A (de)
EP (1)	EP0348360B1 (de)
JP (1)	JPH0623109B2 (de)
KR (1)	KR900000092A (de)
AT (1)	ATE100322T1 (de)
CA (1)	CA1327003C (de)
DE (1)	DE68912419T2 (de)
IT (1)	IT1219667B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2634374B1 (fr) *	1988-07-19	1993-10-15	Laboratoires Serobiologiques	Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
JP3459013B2 (ja) *	1993-05-19	2003-10-20	株式會社緑十字	ウリジンを有效成分とする關節炎治療剤
IT1290781B1 (it) *	1996-05-28	1998-12-10	Polifarma Spa	Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US5962459A (en) *	1996-05-28	1999-10-05	Polifarma S.P.A.	Therapeutic active agent for treatment of neuron degenerative diseases
US7910548B2 (en) *	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
US8143234B2 (en)	1998-07-31	2012-03-27	Massachusetts Institute Of Technology	Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20050203053A1 (en) *	1999-07-30	2005-09-15	Wurtman Richard J.	Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
DK1140104T3 (da)	1998-07-31	2008-01-21	Massachusetts Inst Technology	Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
US20060069061A1 (en) *	1998-07-31	2006-03-30	Dick Wurtman	Compositions containing uridine and choline, and methods utilizing same
US20070004670A1 (en) *	1998-07-31	2007-01-04	Richard Wurtman	Compositions containing citicoline, and methods of use thereof
US8314064B2 (en)	1998-07-31	2012-11-20	Massachusetts Institute Of Technology	Uridine administration stimulates membrane production
US8518882B2 (en)	1998-07-31	2013-08-27	Massachusetts Institute Of Technology	Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US7807654B2 (en)	1998-08-31	2010-10-05	Wellstat Therapeutics Corporation	Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en)	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en)	1998-08-31	2011-03-29	Wellstat Therapeutics Corporation	Compositions and methods for treatment of mitochondrial diseases
EP1808177B1 (de)	1999-02-23	2018-08-08	The Regents of The University of California	Behandlungsmethoden für mitochondriale Erkrankungen
WO2001068104A1 (en) *	2000-03-16	2001-09-20	The Mclean Hospital Corporation	Compounds for the treatment of psychiatric or substance abuse disorders
US6727231B1 (en)	2000-10-12	2004-04-27	Repligen Corporation	Uridine therapy for patients with elevated purine levels
AUPR951101A0 (en)	2001-12-13	2002-01-24	Centre For Molecular Biology And Medicine	Method of treatment
US20050129710A1 (en) *	2003-10-08	2005-06-16	Renshaw Perry F.	Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005112635A2 (en) *	2004-05-13	2005-12-01	Massachusetts Institute Of Technology	Uridine effects on dopamine release
JP5145563B2 (ja) *	2005-11-24	2013-02-20	国立大学法人北海道大学	神経変性疾患治療薬
EP1897937A1 (de) *	2006-09-07	2008-03-12	NeuroProgen GmbH Leipzig	Verfahren zur Züchtung von neuralen Vorläuferzellen
BRPI0817387A2 (pt)	2007-11-02	2015-09-08	Massachusetts Inst Technology	métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
US20100041621A1 (en) *	2008-08-15	2010-02-18	Perry Renshaw	Methods and compositions for improving cognitive performance
BR112012008193A2 (pt)	2009-07-31	2016-03-01	Clera Inc	composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1178044B (it) *	1984-10-09	1987-09-03	Polifarma Spa	Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
JPH0669953B2 (ja) *	1985-08-16	1994-09-07	日産化学工業株式会社	脳脊髄系神経栄養剤
CA1321994C (en) *	1987-10-28	1993-09-07	Reid Von Borstel	Acylated uridine and cytidine and uses thereof

1988
- 1988-06-21 IT IT48118/88A patent/IT1219667B/it active
1989
- 1989-05-24 CA CA000600276A patent/CA1327003C/en not_active Expired - Fee Related
- 1989-06-13 JP JP1150354A patent/JPH0623109B2/ja not_active Expired - Fee Related
- 1989-06-14 DE DE68912419T patent/DE68912419T2/de not_active Expired - Fee Related
- 1989-06-14 AT AT89830264T patent/ATE100322T1/de not_active IP Right Cessation
- 1989-06-14 EP EP89830264A patent/EP0348360B1/de not_active Expired - Lifetime
- 1989-06-19 US US07/367,615 patent/US4960759A/en not_active Expired - Lifetime
- 1989-06-20 KR KR1019890008467A patent/KR900000092A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
CA1327003C (en)	1994-02-15
EP0348360B1 (de)	1994-01-19
JPH0623109B2 (ja)	1994-03-30
EP0348360A3 (de)	1991-10-23
DE68912419D1 (de)	1994-03-03
IT1219667B (it)	1990-05-24
DE68912419T2 (de)	1994-08-04
JPH0245425A (ja)	1990-02-15
IT8848118A0 (it)	1988-06-21
EP0348360A2 (de)	1989-12-27
US4960759A (en)	1990-10-02
KR900000092A (ko)	1990-01-30

Legal Events

Date	Code	Title	Description
1994-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE100322T1 (de)	1994-02-15	Verwendung von uridin zur behandlung nervoeser stoerungen.
DE69012591D1 (de)	1994-10-27	Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
DE58902094D1 (de)	1992-10-01	Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE60216830D1 (de)	2007-02-01	Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60134453D1 (de)	2008-07-31	Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DK0431580T3 (da)	1995-07-24	Substituerede cyclohexanoler med virkning på centralnervesystemet
DE69112895D1 (de)	1995-10-19	Pharmazeutische Verbindungen.
DE10199020I1 (de)	2001-05-23	Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
EP1014881A4 (de)	2000-08-30	Verfahren zur behandlung von neurodegenerativen störungen mittels infusion von nervenwachstumsfaktoren in das gehirn
DE69012261D1 (de)	1994-10-13	Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
EP0616032A3 (de)	1996-12-11	Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase.
DK0531155T3 (da)	1996-06-10	Cerebralaktiverende præparat
IT9041503A0 (it)	1990-01-19	Dispositivo per la cura chirurgica dell'ametropia
DE69822300D1 (de)	2004-04-15	3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
DE69928521D1 (de)	2005-12-29	Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
DE69029734D1 (de)	1997-02-27	Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG
EP0383171A3 (de)	1991-07-24	2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
DE3780542D1 (en)	1992-08-27	Substituierte hexahydroarylchinolizine.
AU560542B2 (en)	1987-04-09	Pyridazine derivatives which have c.n.s. activity
EP0402734A3 (de)	1992-03-18	Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung
ATE80998T1 (de)	1992-10-15	Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
DE59709081D1 (de)	2003-02-13	Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimer'schen Krankheit
ATE136776T1 (de)	1996-05-15	Verwendung von heptastigmin zur behandlung der zerebralen ictus
EP0402733A3 (de)	1992-01-02	Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung
ATE78160T1 (de)	1992-08-15	Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.